NASDAQ:BOLD Audentes Therapeutics (BOLD) Stock Price, News & Analysis → #1 election stock (From Porter & Company) (Ad) Free BOLD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.97▼$10.3950-Day Range$59.97▼$59.9752-Week Range$22.00▼$60.00Volume105,539 shsAverage Volume98,713 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsInsider TradesSocial MediaStock AnalysisAnalyst ForecastsInsider TradesSocial Media Get Audentes Therapeutics alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Audentes Therapeutics Stock (NASDAQ:BOLD)Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Read More Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... BOLD Stock News HeadlinesApril 30, 2024 | finance.yahoo.comMalignant Ascites Market to Observe Growth at a CAGR of 1.2% by 2034 | DelveInsightApril 26, 2024 | seekingalpha.comBOLD Boundless Bio, Inc.May 2, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. April 11, 2024 | bbc.co.ukBold GirlsApril 11, 2024 | businesswire.comBoundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsApril 11, 2024 | morningstar.comBoundless Bio Inc BOLDApril 8, 2024 | businesswire.comBoundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024March 27, 2024 | businesswire.comBoundless Bio Announces Pricing of Initial Public OfferingMay 2, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. November 25, 2023 | cnn.comMarriott Bonvoy Bold credit card review 2023November 4, 2023 | yahoo.comKristen Louelle Is Bold and Beautiful in These 4 Pics in Atlantic CityOctober 27, 2023 | usatoday.comWhat Top 25 upsets are coming this weekend? Bold predictions for Week 5 in college footballApril 27, 2023 | forbes.comHow Bold Leadership Can Help Or Hurt YouApril 23, 2023 | finance.yahoo.comBold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023April 18, 2023 | entrepreneur.comThe Benefits of Bold Leadership and How Leaders Can Develop a Bold MindsetApril 2, 2023 | usatoday.comFive bold predictions for the men's NCAA Tournament's Final FourMarch 26, 2023 | usatoday.comMen's NCAA Tournament 2023: 10 bold predictions for March MadnessMarch 23, 2023 | finance.yahoo.com5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceMarch 17, 2023 | forbes.comTikTok Has A New ‘Bold Glamour’ AI-Powered Filter, Here Are The RisksMarch 12, 2023 | yahoo.comYou but better? Not so fast. Unpacking TikTok's controversial 'Bold Glamour' filterJanuary 18, 2023 | news.yahoo.comOn King's holiday, daughter calls for bold action over wordsJanuary 17, 2023 | dailymail.co.ukIt's blue Monday... Let's embrace it says JO ELVIN, with this season's refreshingly bold take on the colourJanuary 13, 2023 | forbes.comPersonal And Career Success One Bold Move A DayJanuary 5, 2023 | theguardian.comLeBron exits LA and an American F1 star: our bold sports predictions for 2023November 14, 2022 | usatoday.comBold predictions for college football's Week 11 have Alabama and LSU on upset alertOctober 8, 2022 | nypost.comLEGO makes bold claim on how bricks affect mental healthAugust 24, 2022 | investing.comBOLD_old Historical DataSee More Headlines Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2019Today5/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BOLD CUSIPN/A CIK1628738 Webwww.audentestx.com Phone415-818-1001FaxN/AEmployees207Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$25.00 Low Stock Price Target$20.00 Potential Upside/Downside+130.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-128,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-38.00% Debt Debt-to-Equity RatioN/A Current Ratio12.80 Quick Ratio12.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.48) per share Price / Book-1.34Miscellaneous Outstanding Shares46,272,000Free FloatN/AMarket Cap$462.72 million OptionableNo Data Beta2.18 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Matthew R. Patterson (Age 47)Co-Founder, Chairman & CEO Ms. Natalie C. Holles (Age 46)Pres & COO Mr. Thomas P. Soloway (Age 52)Exec. VP & CFO Dr. John T. Gray (Age 56)Sr. VP & Chief Scientific Officer Mr. Andrew H. ChangDirector of Investor RelationsKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHAFate TherapeuticsNASDAQ:FATEHumacyteNASDAQ:HUMAAllogene TherapeuticsNASDAQ:ALLOProKidneyNASDAQ:PROKView All CompetitorsInsidersRa Capital Management, L.P.Bought 312,500 shares on 4/2/2024Total: $5 M ($16.00/share)Kristina BurowBought 200,000 shares on 4/2/2024Total: $3.20 M ($16.00/share)View All Insider Transactions BOLD Stock Analysis - Frequently Asked Questions Should I buy or sell Audentes Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BOLD shares. View BOLD analyst ratings or view top-rated stocks. What is Audentes Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1-year price objectives for Audentes Therapeutics' stock. Their BOLD share price targets range from $20.00 to $25.00. On average, they predict the company's share price to reach $23.00 in the next year. This suggests a possible upside of 130.0% from the stock's current price. View analysts price targets for BOLD or view top-rated stocks among Wall Street analysts. How were Audentes Therapeutics' earnings last quarter? Audentes Therapeutics Inc (NASDAQ:BOLD) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.07. During the same period in the prior year, the business earned ($0.97) earnings per share. What other stocks do shareholders of Audentes Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer (ET), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Intel (INTC), Clovis Oncology (CLVS), AbbVie (ABBV), bluebird bio (BLUE), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN). When did Audentes Therapeutics IPO? Audentes Therapeutics (BOLD) raised $100 million in an initial public offering on Thursday, March 28th 2024. The company issued 6,250,000 shares at $16.00 per share. When does the company's quiet period expire? Audentes Therapeutics' quiet period expires on Tuesday, May 7th. Audentes Therapeutics had issued 6,250,000 shares in its IPO on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. This page (NASDAQ:BOLD) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
